Gene expression profile reveals deregulation of genes with relevant functions in the different subclasses of acute myeloid leukemia

Leukemia

Volumn 19, Issue 3, 2005, Pages 402-409

  Gutierrez N C ^a   Lopez Perez R ^a   Hernandez J M ^a   Isidro, I ^a   Gonzalez B ^a   Delgado, M ^a   Ferminan E ^a   Garcia J L ^a   Vazquez L ^a   Gonzalez M ^a   San Miguel, J F ^a  

^a HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

Author keywords

Expression profile; Microarrays; Myeloid leukemia

Indexed keywords

ANGIOGENIC FACTOR; CD34 ANTIGEN; CORE BINDING FACTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR RECEPTOR 1; GROWTH FACTOR RECEPTOR; HOX PROTEIN; SCATTER FACTOR; SERINE PROTEINASE; SOMATOMEDIN BINDING PROTEIN 2; TRANSCRIPTION FACTOR RUNX3; TRANSFORMING GROWTH FACTOR BETA1; VASCULOTROPIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ARTICLE; BONE MARROW; CELL ADHESION; CELL DIFFERENTIATION; CELL MATURATION; CLUSTER ANALYSIS; CONTROLLED STUDY; DNA MICROARRAY; DOWN REGULATION; FEMALE; GENE CONTROL; GENE EXPRESSION; GENE FUNCTION; GENE TRANSLOCATION; GENETIC CODE; GRANULOCYTE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MONOCYTIC LEUKEMIA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA ISOLATION; UPREGULATION; ACUTE MONOCYTIC LEUKEMIA; CLASSIFICATION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METHODOLOGY; MIDDLE AGED; PHYLOGENY; RETROSPECTIVE STUDY;

ADOLESCENT; ADULT; AGED; CLUSTER ANALYSIS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, LEUKEMIC; HUMANS; LEUKEMIA, MONOCYTIC, ACUTE; LEUKEMIA, MYELOCYTIC, ACUTE; LEUKEMIA, PROMYELOCYTIC, ACUTE; MALE; MIDDLE AGED; PHYLOGENY; RETROSPECTIVE STUDIES;

EID: 20144367446     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2403625     Document Type: Article

References (40)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-2302.
2. Grimwade D, Walker H, Oliver F, Wheatley K, Harrison C, Harrison G et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. Blood 1998; 92: 2322-2333.
3. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000; 96: 4075-4083.
4. Golub TR, Slonim DK, Tamayo P, Huard C, Gaasenbeek M, Mesirov JP et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science 1999; 286: 531-537.
5. Schoch C, Kohlmann A, Schnittger S, Brors B, Dugas M, Mergenthaler S et al. Acute myeloid leukemias with reciprocal rearrangements can be distinguished by specific gene expression profiles. Proc Natl Acad Sci USA 2002; 99: 10008-10013.
6. Debernardi S, Lillington DM, Chaplin T, Tomlinson S, Amess J, Rohatiner A et al. Genome-wide analysis of acute myeloid leukemia with normal karyotype reveals a unique pattern of homeobox gene expression distinct from those with translocation-mediated fusion events. Genes Chromosomes Cancer 2003; 37: 149-158.
7. Kohlmann A, Schoch C, Schnittger S, Dugas M, Hiddemann W, Kern W et al. Molecular characterization of acute leukemias by use of microarray technology. Genes Chromosomes Cancer 2003; 37: 396-405.
8. Valk PJ, Verhaak RG, Beijen MA, Erpelinck CA, van Waalwijk van Doorn-Khosrovani SB, Boer JM et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. N Engl J Med 2004; 350: 1617-1628.
9. Bullinger L, Dohner K, Bair E, Frohling S, Schlenk RF, Tibshirani R et al. Use of gene-expression profiling to identify prognostic subclasses in adult acute myeloid leukemia. N Engl J Med 2004; 350: 1605-1616.
10. Armstrong SA, Staunton JE, Silverman LB, Pieters R, Den Boer ML, Minden MD et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet 2002; 30: 41-47.
11. Virtaneva K, Wright FA, Tanner SM, Yuan B, Lemon WJ, Caligiuri MA et al. Expression profiling reveals fundamental biological differences in acute myeloid leukemia with isolated trisomy 8 and normal cytogenetics. Proc Natl Acad Sci USA 2001; 98: 1124-1129.
12. Qian Z, Fernald AA, Godley LA, Larson RA, Le Beau MM. Expression profiling of CD34+ hematopoietic stem/progenitor cells reveals distinct subtypes of therapy-related acute myeloid leukemia. Proc Natl Acad Sci USA 2002; 99: 14925-14930.
13. Staal FJ, van der Burg M, Wessels LF, Barendregt BH, Baert MR, van den Burg CM et al. DNA microarrays for comparison of gene expression profiles between diagnosis and relapse in precursor-B acute lymphoblastic leukemia: choice of technique and purification influence the identification of potential diagnostic markers. Leukemia 2003; 17: 1324-1332.
14. Chillón MC, Fernández C, García-Sanz R, Balanzategui A, Ramos F, Fernández-Calvo J et al. FLT3-activating mutations are associated with poor prognostic features in AML at diagnosis but they are not an independent prognostic factor. Hematol J 2004; 5: 239-246.
15. Sanz MA, Martín G, Rayón C, Esteve J, González M, Díaz-Mediavilla J et al. A modified AIDA protocol with anthracycline-based consolidation results in high antileukemic efficacy and reduced toxicity in newly diagnosed PML/RARalpha-positive acute promyelocytic leukemia. PETHEMA group. Blood 1999; 94: 3015-3021.
16. Eisen MB, Spellman PT, Brown PO, Botstein D. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
17. Borg I, Groenen PM. Modern Multidimensional Scaling: Theory and Applications. New York: Springer Verlag, 1997.
18. Tusher VG, Tibshirani R, Chu G. Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci USA 2001; 98: 5116-5121.
19. Tibshirani R, Hastie T, Narasimhan B, Chu G. Diagnosis of multiple cancer types by shrunken centroids of gene expression. Proc Natl Acad Sci USA 2002; 99: 6567-6572.
20. Furey TS, Cristianini N, Duffy N, Bednarski DW, Schummer M, Haussler D. Support vector machine classification and validation of cancer tissue samples using microarray expression data. Bioinformatics 2000; 16: 906-914.
21. Ririe KM, Rasmussen RP, Wittwer CT. Product differentiation by analysis of DNA melting curves during the polymerase chain reaction. Anal Biochem 1997; 245: 154-160.
22. Leung KH, Pippalla V, Kreutter A, Chandler M. Functional effects of FGF-13 on human lung fibroblasts, dermal microvascular endothelial cells, and aortic smooth muscle cells. Biochem Biophys Res Commun 1998; 250: 137-142.
23. Inhorn RC, Aster JC, Roach SA, Slapak CA, Soiffer R, Tantravahi R et al. A syndrome of lymphoblastic lymphoma, eosinophilia, and myeloid hyperplasia/malignancy associated with t(8;13)(p11;q11): description of a distinctive clinicopathologic entity. Blood 1995; 85: 1881-1887.
24. Macdonald D, Reiter A, Cross NC. The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1. Acta Haematol 2002; 107: 101-107.
25. Cross NC, Reiter A. Tyrosine kinase fusion genes in chronic myeloproliferative diseases. Leukemia 2002; 16: 1207-1212.
26. Jiang W, Hiscox S, Matsumoto K, Nakamura T. Hepatocyte growth factor/scatter factor, its molecular, cellular and clinical implications in cancer. Crit Rev Oncol Hematol 1999; 29: 209-248.
27. Verstovsek S, Kantarjian H, Estey E, Aguayo A, Giles FJ, Manshouri T et al. Plasma hepatocyte growth factor is a prognostic factor in patients with acute myeloid leukemia but not in patients with myelodysplastic syndrome. Leukemia 2001; 15: 1165-1170.
28. Kini AR, Peterson LA, Tallman MS, Lingen MW. Angiogenesis in acute promyelocytic leukemia: induction by vascular endothelial growth factor and inhibition by all-trans retinoic acid. Blood 2001; 97 3919-3924.
29. Moehler TM, Ho AD, Goldschmidt H, Barlogie B. Angiogenesis in hematologic malignancies. Crit Rev Oncol Hematol 2003; 45: 227-244.
30. Giles FJ, Stopeck AT, Silverman LR, Lancet JE, Cooper MA, Hannah AL et al. SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 2003; 102 795-801.
31. Drabkin HA, Parsy C, Ferguson K, Guilhot F, Lacotte L, Roy L et al. Quantitative HOX expression in chromosomally defined subsets of acute myelogenous leukemia. Leukemia 2002; 16: 186-195.
32. Owens BM, Hawley RG. HOX and non-HOX omeobox genes in leukemic hematopoiesis. Stem Cells 2002; 20: 364-379.
33. Thorsteinsdottir U, Kroon E, Jerome L, Blasi F, Sauvageau G. Defining roles for HOX and MEIS1 genes in induction of acute myeloid leukemia. Mol Cell Biol 2001; 21: 224-234.
34. Kawagoe H, Kawagoe R, Sano K. Targeted down-regulation of MLL-AF9 with antisense oligodeoxyribonucleotide reduces the expression of the HOXA7 and -A10 genes and induces apoptosis in a human leukemia cell line, THP-1. Leukemia 2001; 15: 1743-1749.
35. Hernández JM, Martín G, Gutiérrez NC, Cervera J, Ferro MT, Calasanz MJ et al. Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA. Haematologica 2001; 86: 807-813.
36. van der Reijden BA, Lombardo M, Dauwerse HG, Giles RH, Muhlematter D, Bellomo MJ et al. RT-PCR diagnosis of patients with acute nonlymphocytic leukemia and inv(16)(p13q22) and identification of new alternative splicing in CBFB-MYH11 transcripts. Blood 1995; 86: 277-282.
37. Cleveland DW, Yen TJ. Multiple determinants of eukaryotic mRNA stability. New Biol 1989; 1: 121-126.
38. van der Reijden BA, Massop M, Tonnissen E, van de Locht L, Muus P, De Witte T et al. Rapid identification of CBFB-MYH11-positive acute myeloid leukemia (AML) cases by one single MYH11 real-time RT-PCR. Blood 2003; 101: 5085-5086.
39. Li QL, Ito K, Sakakura C, Fukamachi H, Inoue K, Chi XZ et al. Causal relationship between the loss of RUNX3 expression and gastric cancer. Cell 2002; 109: 113-124.
40. Lutz PG, Houzel-Charavel A, Moog-Lutz C, Cayre YE. Myeloblastin is an Myb target gene: mechanisms of regulation in myeloid leukemia cells growth-arrested by retinoic acid. Blood 2001; 97 2449-2456.